Date

Presenter
古本

2021/12/7
加藤
勝岡
今泉
西村
2021/12/21
安東
坂本
2021/12/28
糸永藤岡2022/1/4
佐藤
2021/12/14

2022/1/11

山田
宮﨑

2022/1/18

クリクラ学生長井渡辺

2022/2/8

澤山
クリクラ学生2022/2/15
加藤
2022/2/22

西村
今泉
古本

2022/3/1
安東
2022/3/8
2022/3/15

坂本
佐藤
藤岡
長井

勝岡
渡辺
山田
2022/3/29
糸永
2022/3/22

Title
JournalYear
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, andLancet Oncol.
2021
dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newlydiagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic
Sci Adv
2021
features and clinical implications
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Blood Adv
2021
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma
Br J Haematol 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
N Engl J Med2022
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Cancer Cell
2021
N Engl J Med
2022
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Mol Cell
2021
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Nat Med2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or moreBlood2021
prior TKIs
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acuteBlood Adv
2021
myeloid leukemia
BCOR gene alterations in hematologic diseases
Blood
2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, UnfavorableJ Clin Oncol
2021
Risk Hodgkin Lymphoma
Blood
2021
Relationship between clone metrics and clinical outcome in clonal cytopenia
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
N Engl J Med
2022
Biol Blood
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy
2020
Marrowfor Acute Myelogenous Leukemia
TransplantSequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous
Blood Cancer J 2021
system lymphoma
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor
J Clin Oncol
2022
T-Cell Therapy
第12回日本血液学会九州地方会 予行
2021年度JOCG リンパ腫班会議 報告
Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection inTransplant Cell
2022
Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis
Ther
Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation
Nat Commun
2021
therapy
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease
J Clin Oncol
2022
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
Blood Adv
2022
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Leukemia
2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor
Blood Advances 2022
DNA
第44回日本造血・免疫細胞療法学会

予行

第44回日本造血・免疫細胞療法学会

予行VolPage22(10)

1378-1390

7(47)eabg9551

5(10)
195(4)
386(4)39(7)386(7)
81(18)
27(10)

2481-2489
571-584351-363
999-1014
640-6543833-3847
1806-1817

138 (21)2031–2041

5(24)5565-5573

138(24)2455–2468

39(20)

2257-2265

138(11)386(1)

965-976
11-23

26(12)

e322-e327

11(7)

131

40(4)

369-381

S26666367(22)00028-8
12(1)

6546

6(4)
36(2)

JCO2101755
1264-1270
394-4026(6)1651-1660